(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
As world leaders enter climate talks, people in poverty have the most at stake - 2Independence from the rat race: How to Save and Contribute Shrewdly
- 3Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- 4Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- 510 Setting up camp Shelters That Offer Both Excellence and Isolation
- Building a Flourishing Business: Illustrations from Business people
- Day to day Temporary Positions That Compensate Fairly in the US
- Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- UB professor shares his experience on almost becoming an astronaut
- Audits of 6 Specialty Mixed drinks
- The German series proving subtitles can be sexy — and wildly addictive
- Hezbollah sees potential win as Israel backs down from disarmament goal
- Renewables cover over 50% of German electricity consumption in Q1
- The most effective method to Pick a Campervan That Offers Something else for Less
